Allogene Therapeutics (ALLO) Other Non-Current Assets (2018 - 2026)

Allogene Therapeutics has reported Other Non-Current Assets for 9 years, with the latest figure at $3.5 million in Q1 2026.

• Quarterly Other Non-Current Assets fell 65.69% year-over-year to $3.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.5 million (down 65.69% YoY) and the FY2025 annual result came in at $3.6 million, down 64.88% from the prior year.
• Other Non-Current Assets retreated to $3.5 million in Q1 2026 per ALLO's latest filing, from $3.6 million in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $10.3 million in Q1 2022 and troughed at $3.5 million in Q3 2025.
• A 5-year average of $8.3 million and a median of $9.6 million in 2023 frame the typical range for Other Non-Current Assets.
• The widest YoY moves for Other Non-Current Assets: up 99.5% in 2025, down 65.87% in 2025.
• Over 5 years, Other Non-Current Assets stood at $10.3 million in 2022, then changed by 0.0% to $10.3 million in 2023, then changed by 0.0% to $10.3 million in 2024, then tumbled by 64.88% to $3.6 million in 2025, then slipped by 2.32% to $3.5 million in 2026.
• According to Business Quant data, Other Non-Current Assets over the past three periods registered $3.5 million, $3.6 million, and $3.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.